Proactive Investors - Run By Investors For Investors

Sareum Holdings PLC raises funds

The proceeds will be used to advance the company drug development programme
The company has raised £1.1mln

Cancer drug discovery and development firm Sareum Holdings Plc (LON:SAR) has raised around £1.1mln by placing shares at 0.7p each.

The proceeds will be used to advance the company drug development programme, and for general working purposes.

After issuing 157.8mln shares, the company now has 2.65bn shares in issue.

Hybridan, joint-broker to the company, said Sareum is “now in an even stronger place going forward” as their lead product Checkpoint Kinase 1 is due to begin Phase I trials by H1 2016. 

“We believe the monies raised will put the company in a better position when they talk to potential licensing partners whilst at the same time enable them to rapidly develop their other pre-clinical programmes,” Hybridan said.

Sareum shares closed at a mid-market price of 0.815p last night; as usually happens when share issues announced, the share price has moved towards the issue price, with Sareum shares trading at 0.618p in the lunchtime trading session.

Why Invest In Sareum Holdings Plc? Read More Here

Register here to be notified of future SAR Company articles
View full SAR profile

Sareum Holdings Plc Timeline

May 17 2016

Related Articles

April 06 2016
Researchers administered Atu027 to patients with pancreatic cancer, one of the hardest strains of the disease to treat.
September 07 2016
It means Futura now has a differentiated product in a market worth US$5bn that , currently dominated by top-selling drugs, such as Viagra and Cialis, that have limitations.
Cancer cells
September 30 2016
Proactive takes a closer look at Vaxil, an Israeli bio-tech firm which listed in Toronto earlier this year. For investors, it could be a cheap way of getting into the exciting world of immunotherapy.

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.